BMS Highlights Data from three P-III Studies of Breyanzi to Treat Various B-Cell Malignancies at ASCO 2024
Shots:
- The TRANSFORM study (N=184; r/r LBCL) of Breyanzi vs SoC showed 29.5mos. vs 2.4mos. EFS; 45.8% vs 19.1% EFS rate at 36mos.; 87% (74% CR) vs 49% (43% CR) ORR; DoR not attained vs 9.1mos. & PFS not attained vs 6.2mos. with 50.9% vs 26.5% PFS rate at 36mos. Patient centric trial (N=61), not attained mOS with 62.8% vs 51.8% OS rate at 36mos.
- In the TRANSCEND NHL 001 study’s MCL arm, Breyanzi had a similar ORR, CR, mDoR, PFS & OS, incl. in heavily pretreated patients with most of the benefit among those with 2-4 prior therapies & shorter DoR in those with >5 prior therapies & refractory to BTK inhibitors
- The TRANSCEND FL study (for r/r FL) subgroup analysis, based on bridging therapy status, showed 93% (N=45) vs 99% (N=79) ORR with & without bridging therapy, respectively; 93% vs 95% CR rates; mDoR, PFS & OS not attained at 18.9mos. follow-up; published in Nature Medicine
Ref: BMS | Image: BMS
Related News:- BMS Reports the US FDA’s Approval of Breyanzi for Treating Mantle Cell Lymphoma
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
